Results 341 to 350 of about 2,974,682 (398)

Phosphodiesterase Type 5 (PDE5) Inhibitors

2003
Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning, Ulrich, Niewöhner, Erwin, Bischoff   +2 more
openaire   +2 more sources

Phosphodiesterase Inhibitors for Cognitive Enhancement

Current Pharmaceutical Design, 2005
An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Gregory M, Rose, Allen, Hopper, Michael, De Vivo, Ashok, Tehim   +3 more
openaire   +2 more sources

Phosphodiesterase inhibitors in clinical urology

Expert Review of Clinical Pharmacology, 2013
To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the ...
Stefan, Ückert, Markus A, Kuczyk, Matthias, Oelke   +2 more
openaire   +2 more sources

Phosphodiesterase Inhibitors: History of Pharmacology

2011
The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as PDE.
Christian, Schudt, Armin, Hatzelmann, Rolf, Beume, Hermann, Tenor   +3 more
openaire   +2 more sources

Phosphodiesterase inhibitors in airways disease

European Journal of Pharmacology, 2006
Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5' monophosphates, and exist as 11 families. They are found in a variety of inflammatory and structural cells.
openaire   +2 more sources

Phosphodiesterase Inhibitors in Raynaud's Phenomenon

Annals of Pharmacotherapy, 2006
Objective: TO evaluate the efficacy of the phosphodiesterase type 5 (PDE5) inhibitors in the treatment of Raynaud's phenomenon. Data Sources: Searches of MEDLINE (1966–March 2006) and Web of Science (1980–March 2006) were conducted; search terms were sildenafil, tadalafil, vardenafil, phosphodiesterase, and Raynaud.
openaire   +2 more sources

Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.

Drugs of Today, 2017
D. Paton
semanticscholar   +1 more source

Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study

Journal of dermatological treatment (Print), 2016
F. Ohba, S. Matsuki, S. Imayama, K. Matsuguma, S. Hojo, Maiko Nomoto, H. Akama   +6 more
semanticscholar   +1 more source

A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction

Journal of Cardiovascular Pharmacology and Therapeutics, 2018
R. Kloner, P. Goggin, I. Goldstein, G. Hackett, M. Kirby, I. Osterloh, J. Parker, R. Sadovsky   +7 more
semanticscholar   +1 more source

Phosphodiesterase inhibitors

Baillière's Clinical Anaesthesiology, 1994
J. Boldt, G. Hempelmann
openaire   +1 more source